With IBI Buy, Thermo Aims to Expand In-House Diagnostics Offerings, Position Mass Spec for the Clinic | GenomeWeb

By Adam Bonislawski

With its purchase this month of Intrinsic Bioprobes, Thermo Fisher Scientific is aiming not only to expand its reagent offerings for clinical proteomics customers, but also accelerate its own in-house assay development program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.